Lumican modulates adipocyte function in obesity-associated type 2 diabetes

Abstract

Obesity-associated type 2 diabetes (DM) leads to adipose tissue dysfunction. Lumican is a proteoglycan implicated in obesity, insulin resistance (IR), and adipocyte dysfunction. Using human visceral adipose tissue (VAT) from subjects with and without DM, we studied lumican effects on adipocyte function. Lumican was increased in VAT and adipocytes in DM. Lumican knockdown in adipocytes decreased lipolysis and improved adipogenesis and insulin sensitivity in VAT adipocytes in DM, while treatment with human recombinant lumican increased lipolysis and impaired insulin-sensitivity in an ERK-dependent manner. We demonstrate that lumican impairs adipocyte metabolism, partially via ERK signalling, and is a potential target for developing adipose tissue-targeted therapeutics in DM.

Description

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords

Lumican, adipose tissue, diabetes, insulin resistance, ERK

Citation

Clarissa Strieder-Barboza, Carmen G. Flesher, Lynn M. Geletka, Tad Eichler, Olukemi Akinleye, Alexander Ky, Anne P. Ehlers, Carey N. Lumeng & Robert W. O’Rourke (2022) Lumican modulates adipocyte function in obesity-associated type 2 diabetes, Adipocyte, 11:1, 665-675, DOI: 10.1080/21623945.2022.2154112

Collections